Experimental research at the University of Oklahoma aims to treat metastatic cancer
Researchers at the University of Oklahoma are testing an experimental treatment for metastatic cancer focusing on pancreatic cancer. Metastasis, the ...
Tag: metastatic
Novel therapeutic agents may reduce the oncogenesis of metastatic prostate cancer
Philadelphia, April 13, 2022 – Researchers have found that treating prostate cancer cells with novel cyclin-dependent kinase 19 (CDK19) and ...
New radionuclide combination therapy safe and effective in metastatic prostate cancer patients
A novel nuclear medicine combination therapy has been proven safe and effective in men with heavily pre-treated metastatic castration-resistant prostate ...
Assessing the invasive and metastatic potential of cancer cells from a tissue section
Rac and Cdc42* are well-studied low molecular weight G proteins that regulate the ability of cancer cells to move, which ...
Metastatic prostate cancer on the rise since decrease in cancer screenings
LOS ANGELES — A new study from Keck Medicine of USC finds that the incidence rate of metastatic prostate cancer ...
Ribociclib added to endocrine therapy extends survival in postmenopausal patients with metastatic breast cancer
A study led by researchers from The University of Texas MD Anderson Cancer Center showed a significant overall survival benefit ...
Novel radioligand therapy proven superior for metastatic prostate cancer patients
Reston, VA—A novel prostate cancer treatment—225Ac-PSMA-617 radioligand therapy—has been shown to increase the progression free survival (PFS) and overall survival ...
City of Hope and Osel announce live biotherapeutic product CBM588 may enhance efficacy of immunotherapy for patients with metastatic kidney cancer
LOS ANGELES and MOUNTAIN VIEW, Calif. — City of Hope, one of the largest cancer research and treatment organizations in ...
MYC inhibition halts metastatic breast cancer progression by blocking tumor growth, invasion & seeding
Credit: Vall d'Hebron Institute of Oncology (VHIO). VHIO-led research published in Cancer Research Communications shows that the first-in-class MYC ...
Data from Codiak’s exoASO™-STAT6 preclinical development program for the treatment of primary and metastatic hepatic cancers published in Science Advances
CAMBRIDGE, Mass., February 18, 2022 — Codiak BioSciences, Inc. (NASDAQ: CDAK), a clinical-stage biopharmaceutical company pioneering the development of exosome-based ...
Three-drug combination prolongs survival in men with metastatic, hormone-sensitive prostate cancer
BOSTON – Results from an international, randomized, double-blind, placebo-controlled, phase 3 clinical trial indicate that adding the androgen-receptor inhibitor darolutamide to androgen-deprivation ...
NIH study advances personalized immunotherapy for metastatic breast cancer
An experimental form of immunotherapy that uses an individual’s own tumor-fighting immune cells could potentially be used to treat people ...
Examining use of extended radiation therapy for metastatic cancer near end of life
What The Study Did: This study investigated how common the use of extended radiation therapy is to treat metastatic cancer ...
Metabolic vulnerabilities could be new targets for metastatic breast cancer
Metabolic differences could explain why some metastatic breast cancer cells rapidly generate tumors after migrating from primary tumors to the ...
SABCS: Subgroup analysis of trastuzumab deruxtecan shows ‘encouraging’ results in controlling stable brain metastases in HER2-positive metastatic breast cancer
EMBARGOED TIPSHEET SABCS: Subgroup analysis of trastuzumab deruxtecan (T-DXd) shows ‘encouraging’ results in controlling stable brain metastases in HER2-positive metastatic ...
Clogged flow: Cancer cells impair blood flow in metastatic lymph nodes
If not caught quickly, cancer cells often spread to other organs in a process called metastasis. Lymph nodes (LNs) are ...
First-line CDK 4/6 inhibition shows overall survival benefit for metastatic breast cancer
Lugano, Switzerland, 19 September 2021 – Adding a CDK 4/6 inhibitor to first-line hormonal treatment prolongs survival by one year for postmenopausal women with hormone receptor (HR) positive, HER2 negative ...
Immunotherapy prolongs survival in recurrent, persistent or metastatic cervical cancer
Lugano, Switzerland, 18 September 2021 – The addition of immunotherapy to standard first-line treatment extends survival by eight months for patients with recurrent, persistent or metastatic cervical cancer, according to late breaking results from the KEYNOTE-826 ...